



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



DFT investigation of atazanavir as potential inhibitor for 2019-nCoV coronavirus M protease

Siyamak Shahab^{a,b,c,*}, Masoome Sheikhi^d, Radwan Alnajjar^{e,f}, Sultan Al Saud^a, Maksim Khancheuski^a, Aleksandra Strogova^a

^a Belarusian State University, ISEI BSU, Minsk, Republic of Belarus

^b Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus, 13 Surganov Str., Minsk 220072, Republic of Belarus

^c Institute of Chemistry of New Materials, National Academy of Sciences of Belarus, 36 Skarina Str., Minsk 220141, Republic of Belarus

^d Young Researchers and Elite Club, Gorgan Branch, Islamic Azad University, Gorgan, Iran

^e Department of Chemistry, Faculty of Science, University of Benghazi, Benghazi, Libya

^f Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa



ARTICLE INFO

Article history:

Received 28 July 2020

Revised 11 October 2020

Accepted 14 October 2020

Available online 17 October 2020

Keywords:

Atazanavir

Coronavirus 2019-nCoV

DFT

Molecular docking

Electronic properties

ABSTRACT

Atazanavir (ATZ) is an antiviral drug synthesized. ATZ is being investigated for potential application against the Coronavirus 2019-nCoV. To find candidate drugs for 2019-nCoV, we have carried out a computational study to screen for effective available drug ATZ which may work as an inhibitor for the Mpro of 2019-nCoV. In the present work, the first time the molecular structure of ATZ molecule has been studied using Density Functional Theory (CAMB3LYP/6-31G*) in solvent water. The electronic properties, atomic charges, MEP, NBO analysis, and excitation energies of ATZ have also been studied. The interaction of ATZ compound with the Coronavirus was performed by molecular docking studies.

© 2020 Elsevier B.V. All rights reserved.

1. Introduction

Atazanavir with the brand name Reyataz among others is an azapeptide protease inhibitor (PI) and has been approved both by the FDA and the European Medicines Agency (EMA) for the treatment of HIV infectious disease [1]. Atazanavir (ATZ) has fewer restrictions rather than other classic PIs including offering a lower pill burden, a more favorable lipid profile, and a lower incidence of gastrointestinal symptoms [1]. ATZ drug may become a new option for first-line PIs or salvage therapy in patients with moderate experience with PIs. Atazanavir is a highly selective and effective inhibitor of the HIV-1 protease enzyme. Early development studies performed in the late 1990s confirmed that it blocked the cleavage of both gag and gag-pol precursor proteins in HIV-infected cells, leading to a release of non-infectious and immature viral particles [2]. Atazanavir is an azapeptide HIV-1 PI that prevents the formation of mature virions through the potent and selective inhibition of viral Gag and Gag-Pol polyprotein processing in HIV-1-infected cells [3]. Atazanavir

may cause side effects. Many side effects from HIV medicines, such as nausea or occasional dizziness, are manageable. See the Clinical Info fact sheet on HYPERLINK "<https://hivinfo.nih.gov/fact-sheet/hiv-medicines-and-side-effects>" \t "_blank for more information. Some side effects of atazanavir can be serious. Serious side effects of atazanavir include changes in heart rhythm, severe rash, liver problems, and life-threatening drug interactions. (See section above: What are the most important things to know about atazanavir?). Other possible side effects of atazanavir include: mild rash, chronic kidney disease, Kidney stones. Contact your health care provider if you have pain in your lower back or lower stomach area, blood in your urine, or pain when urinating, gallbladder problems. Contact your health care provider right away if you develop symptoms of gallbladder problems (pain in your right or middle upper stomach area, fever, nausea and vomiting, or jaundice), diabetes and high blood sugar (hyperglycemia), changes in your immune system (called immune reconstitution inflammatory syndrome or IRIS). IRIS is a condition that sometimes occurs when the immune system begins to recover after treatment with an HIV medicine. As the immune system gets stronger, it may have an increased response to a previously hidden infection, Changes in body

* Corresponding author.

E-mail address: siyamakshahab@mail.ru (S. Shahab).



Fig. 1. The obtained conformers with relative energies computed at PM6 in gas.

fat (lipodystrophy syndrome), Increased bleeding problems in people with hemophilia [4-6].

According to the openly published data, in 2019, a novel Coronavirus 2019-nCoV was found to cause Severe Acute Respiratory symptoms and rapid pandemic in China. On 13, 16, and 21 January, respectively, Thailand, Japan, and Korea confirmed the detection of human infection with 2019-nCoV from China [7]. Liu and co-workers have been suggested 10 drugs such as Colistin, Valrubicin, Icatibant, Bepotastine, Epirubicin, Epoprostenol, Vapreotide, Aprepitant, Caspofungin, Perphenazine as a candidate against 2019-nCoV coronavirus [8]. They have been studied the interaction of the mentioned drugs with the Coronavirus by molecular docking studies. To find candidate drugs for 2019-nCoV, we have performed a theoretical study for evaluating the usability of Atazanavir ($C_{38}H_{52}N_6O_7$) drug as an inhibitor for the Mpro of 2019-nCoV. The molecular docking approach is used to model the interaction between a molecule and a protein at the atomic level, which allows us to characterize the behavior of molecules in the binding site of target proteins as well as to elucidate fundamental biochemical processes [9,10]. We have recently suggested Triazavirin drug as a candidate against 2019-nCoV coronavirus [11]. We have been investigated the interaction of the mentioned drug with the Coronavirus by molecular docking studies. In this work, the first time the structure of the Atazanavir (ATZ) molecule has been investigated using Density Functional Theory (DFT: CAMB3LYP/6-31G*) in solvent water. The electronic properties, MEP and NBO

analysis, excitation energies ATZ have also been calculated. The interaction of ATZ drug with the Coronavirus was performed by molecular docking studies.

2. Computational methods

In the current study, the first conformational analysis was performed for the compound Atazanavir (ATZ). Then, the quantum chemical calculations have been carried out for the most stable conformation using the Density Functional Theory (DFT) method at CAMB3LYP/6-31G* level of theory [12] in solvent water by the Gaussian 09W program package [13] on a Pentium IV/4.28 GHz personal computer. The Polarized Continuum Model (PCM) [14] was used for the calculations of solvent effect. We have used Time Dependent Density Functional Theory (TD-DFT) [15] for calculation of the electronic transitions of the ATZ molecule. The electronic properties such as E_{HOMO} , E_{LUMO} , HOMO-LUMO energy gap, dipole moment (D_M), Mulliken atomic charges, and natural charge [16] of the ATZ molecule were obtained. The optimized molecule, molecular electrostatic potential (MEP) surface, HOMO, and LUMO surfaces were visualized using GaussView 05 program [17]. Interaction between the structure of Coronavirus 2019-nCoV and ATZ has been calculated by HyperChem Professional 08 [18], PyMOL, and Molegro Molecular Viewer software programs. The protein sequences of 2019-nCoV were downloaded from GenBank (<http://www.ncbi.nlm.nih.gov>). The crystal structure of SARS-CoV^{Mpro} (PDB ID: 1UJ1) was downloaded from Protein Data Bank (PDB, <http://www.rcsb.org>). Preparation of the protein receptor we have started with a procedure in which have deleted all water molecules and ligands except for necessary cofactors. We have examined the protein for gaps and follow procedures for building and optimizing the missing loops. We have added hydrogens and optimize the hydrogen-bonding network. Finally, we have saved cleaned structure for docking.

3. Results and discussion

Since the Atazanavir (ATZ) molecule is flexible a conformation search was conducted first to obtain the minimal structure, the




Fig. 2. Optimized structure of the ATZ by CAMB3LYP/6-31G* method.

Table 1

Selected optimized geometrical parameters (Bond lengths (Å) and Bond angles (°)) of the ATZ molecule.

Bond	Bond lengths (Å)	Bond	Bond angles (Å)
N1-C2	1.468	N1-C2-C5	115.22
N1-N3	1.385	N1-N3-C6	120.73
N1-C4	1.469	N1-C4-C18	109.03
C2-C5	1.516	N1-N3-H54	119.11
N3-C6	1.349	C2-N1-N3	112.79
C4-C18	1.528	C2-N1-C4	117.52
C6-C7	1.529	N3-N1-C4	114.97
C6-O8	1.233	N3-C6-C7	115.75
C7-N9	1.454	N3-C6-O8	123.09
C7-C14	1.561	C7-C6-O8	121.15
C14-C15	1.534	C7-N9-H58	117.11
C14-C16	1.534	C6-C7-C14	113.52
C14-C17	1.533	N9-C7-C14	112.77
N9-C10	1.353	C7-C14-C17	111.97
C5-C41	1.398	N9-C10-O11	112.87
C5-C45	1.397	N9-C10-O12	123.62
C10-O11	1.342	C10-O11-C13	116.13
C10-O12	1.225	O11-C10-O12	123.49
O11-C13	1.433	C15-C14-C17	109.52
C18-C19	1.538	C16-C14-C17	109.23
C18-O20	1.418	C18-O20-H73	109.20
C19-N21	1.456	C19-N21-C23	122.96
C19-C22	1.533	C19-N21-H74	119.20
N21-C23	1.348	C19-C22-C35	114.14
C22-C35	1.511	N21-C19-C22	110.94
C23-O25	1.232	N21-C23-O25	122.90
C23-C24	1.537	C22-C35-C36	120.84
C24-N26	1.457	C23-C24-N26	111.91
C24-C27	1.561	C23-C24-C27	103.68
C27-C28	1.535	C24-N26-H78	119.64
C27-C29	1.536	N26-C31-C32	112.22
C27-C30	1.534	N26-C31-O33	123.94
N26-C31	1.357	C28-C27-C30	108.85
C31-O32	1.341	C29-C27-C30	109.81
C31-O33	1.224	C31-O32-C34	116.31
O32-C34	1.434	O32-C31-O33	123.82
C35-C36	1.395	C35-C36-C37	121.03
C35-C40	1.398	C41-C42-C43	120.73
C36-C37	1.393	C42-C43-C44	118.23
C37-C38	1.391	C42-C43-C46	120.25
C38-C39	1.394	C43-C44-C45	120.87
C39-C40	1.391	C43-C46-N47	116.87
N3-H54	1.016	C44-C43-C46	121.49
N9-H58	1.011	C46-N47-C48	118.59
N21-H74	1.011	C48-C49-C50	117.90
N26-H78	1.010	C49-C50-C51	118.98

conformation search was done using the conformer distribution tool implemented in Spartan 16 software, molecular mechanics MMFF94 [19] was used with 10,000 conformers as a limit. Six conformers were identified as a minimum, further optimized at the PM6 level used to enhance the MMFF output. The energy difference was in 0.00 – 12.86 kcal/mol range (Fig. 1).

In the next step, the most stable conformation of ATZ in the ground state was optimized using CAMB3LYP/6-31G* level of theory (Fig. 2). The theoretical parameters such as Bond lengths (Å) and Bond angles (°) are shown in and Table 1.

The HOMO and LUMO orbitals are the frontier molecular orbitals (FMOs) that have an important role in chemical stability, optical properties, UV/Vis spectrum, and kinetic reactivity properties of the molecules [20]. The energy difference between HOMO and LUMO orbitals shows an energy gap (E_g) which is related to the hardness or softness of molecules. We obtained the theoretical energies of HOMO (E_{HOMO}) and the LUMO (E_{LUMO}) orbitals and the electronic properties of the ATZ using CAMB3LYP/6-31G* level of theory; the results are reported in Table 2. Fig. 3 shows the pictures of HOMO and LUMO orbitals. The HOMO orbital of ATZ is mainly centralized on the nitrogen atoms (N1 and N3), the oxygen

Table 2

The calculated electronic properties of the ATZ.

Property	CAMB3LYP
Electronic Energy (a.u.)	-2333.453
D_M (Debye)	14.33
Point Group	C1
E_{HOMO} (eV)	-7.9710
E_{LUMO} (eV)	-0.3906
E_g (eV)	7.5804
I (eV)	7.97
A (eV)	0.39
χ (eV)	4.18
η (eV)	3.79
μ (eV)	-4.18
ω (eV)	2.30
S (eV)	0.13

Table 3

The selected calculated Mulliken and NBO charges (e) of the ATZ.

Atoms	NBO	Mulliken
N1	-0.372	-0.139
N3	-0.469	-0.008
N9	-0.684	-0.689
N21	-0.664	-0.146
N26	-0.700	-0.814
N47	-0.490	-0.264
O8	-0.700	-0.478
O11	-0.580	-0.346
O12	-0.723	-0.586
O20	-0.824	-0.663
O25	-0.704	-0.470
O32	-0.576	-0.270
O33	-0.716	-0.537
C6	0.715	-0.457
C10	0.959	0.855
C15	-0.692	-0.538
C16	-0.686	-0.504
C17	-0.694	-0.660
C22	-0.491	-0.095
C23	0.713	-0.220
C28	-0.684	-0.592
C29	-0.686	-0.432
C30	-0.694	-0.386
C31	0.960	0.482
H52	0.263	0.259
H53	0.263	0.246
H54	0.437	0.471
H58	0.459	0.486
H72	0.277	0.253
H73	0.525	0.590
H74	0.449	0.489
H75	0.278	0.265
H77	0.291	0.266
H78	0.453	0.487

atom of the carbonyl group (O8), and the oxygen atom of the hydroxyl group (O20), whereas the LUMO orbital is centralized on the N1 atom, double bonds (-C=C- and -C=N-) of one of phenyl rings and pyrimidine ring. Therefore, most of the charge transfer from the HOMO to LUMO in ATZ takes place with the contribution of lone pairs of and pi (π) bonds. The E_g value of ATZ was calculated at about 7.5804 eV. The E_{HOMO} and E_{LUMO} are related to the ionization potential ($I = -E_{HOMO}$) and the electron affinity ($A = -E_{LUMO}$). The global hardness (η), electronegativity (χ), electronic chemical potential (μ) and electrophilicity (ω), and chemical softness (S) parameters of the ATZ are calculated with the following equations [21-24]:

$$(\eta = I - A/2) \quad (1)$$

Table 4
Significant donor–acceptor interactions and second order perturbation energies of the ATZ.

Donor (i)	Occupancy	Acceptor (j)	Occupancy	E ⁽²⁾ ^a /kcal/mol	E(j)-E(i) ^b a.u.	F(i, j) ^c a.u.
σ (N3-C6)	1.98979	σ^* (N1-C2)	0.03037	1.18	1.35	0.036
σ (C7-N9)	1.98077	σ^* (C10-O12)	0.29975	1.06	1.01	0.032
σ (C14-C15)	1.97710	σ^* (C16-H66)	0.00655	1.92	1.19	0.043
σ (N21-C23)	1.98929	σ^* (C19-N21)	0.02812	1.68	1.34	0.043
σ (C31-O33)	1.99190	σ^* (N26-C31)	0.06423	1.32	1.59	0.041
σ (C41-C42)	1.97881	σ^* (C43-C46)	0.03426	3.66	1.30	0.062
π (C5-C45)	1.64737	π^* (C41-C42)	0.31237	28.63	0.036	0.092
		π^* (C43-C44)	0.35947	31.12	0.36	0.095
π (C35-C36)	1.65717	π^* C37-C38)	0.33006	31.45	0.036	0.095
		π^* (C39-C40)	0.32465	29.00	0.36	0.092
π (C37-C38)	1.67086	π^* (C35-C36)	0.33704	28.67	0.37	0.092
		π^* (C39-C40)	0.32465	30.63	0.36	0.094
π (C39-C40)	1.67400	π^* (C35-C36)	0.33704	30.74	0.37	0.095
		π^* (C37-C38)	0.33006	29.15	0.36	0.092
π (C41-C42)	1.65951	π^* (C5-C45)	0.35149	31.04	0.37	0.095
		π^* (C43-C44)	0.35947	29.31	0.36	0.093
π (C43-C44)	1.63676	π^* (C5-C45)	0.35149	30.62	0.36	0.094
		π^* (C41-C42)	0.31237	29.15	0.36	0.093
		π^* (C46-N47)	0.42196	16.79	0.33	0.067
π (C46-N47)	1.70909	π^* (C48-C49)	0.30173	37.89	0.41	0.112
		π^* (C50-C51)	0.29704	18.15	0.41	0.077
π (C48-C49)	1.63073	π^* (C46-N47)	0.42196	26.27	0.34	0.085
		π^* (C50-C51)	0.29704	33.83	0.37	0.101
π (C50-C51)	1.64304	π^* (C46-N47)	0.42196	42.21	0.34	0.109
		π^* (C48-C49)	0.30173	25.28	0.36	0.087
π^* (C46-N47)	0.42196	π^* (C48-C49)	0.30173	165.42	0.02	0.094
		π^* (C50-C51)	0.29704	171.64	0.03	0.100
n1(N1)	1.89493	σ^* (C2-C5)	0.03299	8.71	0.82	0.077
		σ^* (N3-H54)	0.03212	9.55	0.82	0.081
n1(N3)	1.68960	π^* (C6-O8)	0.29581	82.19	0.39	0.161
n2(O8)	1.87349	σ^* (N3-C6)	0.07037	25.30	0.88	0.135
		σ^* (C6-C7)	0.06443	22.00	0.76	0.118
n1(N9)	1.73155	σ^* (C10-O12)	0.29975	47.73	0.49	0.138
n1(O11)	1.95784	π^* (C10-O12)	0.11541	9.11	1.12	0.092
n2(O11)	1.82707	σ^* (C10-O12)	0.29975	32.51	0.57	0.126
n2(O12)	1.85596	σ^* (N9-C10)	0.06299	24.61	0.86	0.133
		σ^* (C10-O11)	0.09572	36.98	0.75	0.151
n1(N21)	1.68253	π^* (C23-O25)	0.28366	76.25	0.40	0.158
n2(O25)	1.88365	σ^* (N21-C23)	0.06630	27.02	0.88	0.140
		σ^* (C23-C24)	0.07220	22.01	0.75	0.116
n1(N26)	1.74199	π^* (C31-O33)	0.33447	59.38	0.42	0.144
n1(O32)	1.95858	σ^* (C31-O33)	0.06865	10.65	1.20	0.102
n2(O32)	1.82199	π^* (C31-O33)	0.33447	45.51	0.50	0.140
n2(O33)	1.85515	σ^* (N26-C31)	0.06423	24.93	0.86	0.133
		σ^* (C31-O32)	0.09568	37.03	0.76	0.151
n1(N47)	1.92555	σ^* (C46-C51)	0.03136	11.16	1.03	0.097
		σ^* (C48-C49)	0.02559	10.76	1.04	0.096

^a E⁽²⁾ Energy of hyperconjugative interactions,^b Energy difference between donor and acceptor i and j NBO orbitals,^c F(i, j) is the Fock matrix element between i and j NBO orbitals.

$$(\chi = I + A/2) \quad (2)$$

$$(\mu = -(I + A)/2) \quad (3)$$

$$(\omega = \mu^2/2\eta) \quad (4)$$

$$(S = 1/2\eta) \quad (5)$$

in which is reported in Table 2. The density of states spectrum (DOS) of the ATZ is shown in Fig. 3.

The MEP map of the optimized molecule ATZ was computed and given in Fig. 4. The MEP surface of the molecule is related to the electronegativity, the electrophilic, and nucleophilic reactive of the molecules and the partial charges on the different atoms [25]. The difference of the electrostatic potential at the maps is shown in different colors. The electron-rich sites, partially negative charge, slightly electron-rich regions, positive charge or electron-poor and neutral sites in the MEP maps appear as red, orange, yellow, blue,

and green colors, respectively [26]. In the MEP map of ATZ, the oxygen atoms such as O_a, O_b, O_c, O_d with red color display electron rich regions, which is due to the lone pair electrons. The hydrogen atoms such as H_a, H_b, H_c with blue color show the electron-poor and electrophilic sites. The regions with green color show the sites with zero potential and neutral regions. The electrophilic and nucleophilic regions of the ATZ illustrate the interaction with other molecules in chemical reactions.

The calculated Mulliken atomic and natural charges of the ATZ molecule are summarized in Table 3 and the diagrams of charges are shown in Fig. 5. The atomic charges have an important role in the prediction of the electrophilic and nucleophilic reactive regions of the molecules. The atomic charges can be illustrated the parameters such as dipole moments, electronic structures, polarizability, and chemical reactivity of molecules. The Mulliken and natural charges for the oxygen and nitrogen atoms are the negative values. The O20 atom has the highest negative charge (NBO: -0.824e and Mulliken: -0.663e) comparing with other oxygen atoms and the N26 atom has the highest negative charge (NBO: -0.824e and

Table 5
Electronic absorption spectrum of the ATZ molecule calculated by CAM-B3LYP/6-31G* method.

Excited State	Wavelength (nm)	Excitation Energy (Ev)	Configurations Composition (corresponding transition orbitals)	Oscillator Strength (f)
$S_0 \rightarrow S_1$	253.70	4.88	H→L (85%), H-2→L (2%), H→L+1 (3%)	0.69
$S_0 \rightarrow S_{11}$	202.55	6.12	H-5→L (16%), H→L+3 (11%), H-9→L (7%), H-2→L+2 (2%), H-2→L+3 (2%), H-2→L+11 (9%), H-2→L+13 (9%), H→L+1 (8%), H→L+2 (7%)	0.10
$S_0 \rightarrow S_{13}$	196.94	6.29	H-9→L (12%), H-5→L+3 (11%), H→L+2 (21%), H-13→L (5%), H-9→L+1 (3%), H-5→L (3%), H-5→L+1 (6%), H-5→L+2 (4%), H→L+3 (3%), H→L+7 (2%), H→L+8 (2%), H→L+20 (4%)	0.11
$S_0 \rightarrow S_{14}$	194.57	6.37	H→L+2 (19%), H→L+7 (17%), H-13→L (5%), H-12→L (4%), H-9→L+1 (3%), H-5→L+1 (5%), H-5→L+2 (4%), H-5→L+3 (9%), H→L+1 (3%), H→L+3 (2%), H→L+4 (4%), H→L+16 (3%)	0.12
$S_0 \rightarrow S_{18}$	185.74	6.67	H-9→L+1 (14%), H-5→L+1 (13%), H-13→L (8%), H-12→L (7%), H-12→L+1 (4%), H-5→L+3 (3%), H-2→L+2 (4%), H→L+1 (3%), H→L+3 (6%), H→L+4 (3%), H→L+13 (2%), H→L+20 (3%)	0.40
$S_0 \rightarrow S_{20}$	184.22	6.73	H-3→L+2 (10%), H-3→L+4 (11%), H-3→L+6 (24%), H-1→L+6 (14%), H-3→L+3 (6%), H-3→L+7 (3%), H-3→L+9 (5%), H-2→L+2 (2%), H-1→L+4 (6%)	0.39

*H-HOMO, L-LUMO

**In these table the transitions with $f \geq 0.1$ are presented.




Fig. 3. The shape of HOMO and LUMO orbitals and DOS plot of the molecule ATZ.

Mulliken: $-0.663e$) rather than other nitrogen atoms. All the hydrogen atoms display a positive charge. The H54, H58, H73, H74, H78 atoms have the highest positive charge about rather than other hydrogen atoms due to the attachment to electron-withdrawing nitrogen (nitro group) and oxygen atoms (hydroxyl group).

NBO analysis is an important method for investigation of intra- and inter-molecular bonding and interaction between bonds and studying charge transfer in molecules [27]. The filled and empty NBOs and the stabilization energy ($E^{(2)}$) calculated from the second-order micro disturbance theory of the ATZ molecule are represented in Table 4.




Fig. 4. MEP map of the molecule ATZ.




Fig. 5. Mulliken and natural charges distribution of the ATZ.

The electron delocalization from the electron donor orbitals to the electron acceptor orbitals represented a conjugative electron transfer process between them [28]. For each electron donor orbital (i) and electron acceptor orbital (j), the interacting stabilization energy $E^{(2)}$ associated with the delocalization $i \rightarrow j$ is computed according to the following equation [28]:

$$E^{(2)} = \Delta E_{ij} = q_i \frac{F(i, j)^2}{s_j - s_i} \quad (6)$$

in which q_i is the electron donor orbital occupancy, ε_j and ε_i are diagonal elements and $F(i, j)$ is the off-diagonal NBO Fock matrix element [27]. The stabilization energy ($E^{(2)}$) shows the value of

the participation of electrons in the resonance between atoms [27]. The greater $E^{(2)}$ value, the most intensive is the interaction between donor and acceptor orbitals, i.e. the more donation tendency from electron donors to electron acceptors and the most extent of conjugation of the whole molecule. NBO analysis has been performed for the ATZ molecule using CAMB3LYP/6-31G* level of theory. The selected intramolecular hyperconjugative interactions of the ATZ such as $\pi \rightarrow \pi^*$, $\pi^* \rightarrow \pi^*$, $\sigma \rightarrow \sigma^*$, $n \rightarrow \pi^*$ and $n \rightarrow \sigma^*$ transitions are reported in Table 4. According to obtained results, the important $\pi \rightarrow \pi^*$ transitions of aryl rings is observed for $\pi(C4-C45) \rightarrow \pi^*(C43-C44)$, $\pi(C35-C36) \rightarrow \pi^*(C37-C38)$, $\pi(C41-C42) \rightarrow \pi^*(C5-C45)$, $\pi(C46-N47) \rightarrow \pi^*(C48-C49)$, $\pi(C48-$




Fig. 6. UV spectra of the ATZ molecule calculated by TD-CAMB3LYP/6-31G* method.

C49) $\rightarrow\pi^*(C50-C51)$, $\pi(C50-C51)\rightarrow\pi^*(C46-N47)$ interactions with stabilization energies ($E^{(2)}$) of 31.12 kcal/mol, 31.45 kcal/mol, 31.04 kcal/mol, 37.89 kcal/mol, 33.83 kcal/mol, 42.21 kcal/mol respectively, and the $\pi(C50-C51)\rightarrow\pi^*(C46-N47)$ interaction at the pyrimidine ring has the higher resonance energy (42.21 kcal/mol) rather than other $\pi\rightarrow\pi^*$ interactions. The highest resonance energies of the ATZ is observed for $\pi^*(C46-N47)\rightarrow\sigma^*(C48-C49)$ and $\pi^*(C46-N49)\rightarrow\pi^*(C50-C51)$ transitions at the pyrimidine ring with stabilization energies of 165.42 kcal/mol and 171.64 kcal/mol, respectively. The $n1(N3)\rightarrow\pi^*(C6-O8)$, $n1(N21)\rightarrow\pi^*(C23-O25)$, $n1(N26)\rightarrow\pi^*(C31-O33)$, $n2(O32)\rightarrow\pi^*(C31-O33)$ interactions have the highest resonance energies ($E^{(2)}$) of $n\rightarrow\pi^*$ with values of 82.19 kcal/mol, 76.25 kcal/mol, 59.38 kcal/mol, 45.51 kcal/mol, respectively. The important $n\rightarrow\sigma^*$ transition is observed for $n1(N9)\rightarrow\sigma^*(C10-O12)$ with resonance energy ($E^{(2)}$) of 47.73 kcal/mol.

The theoretical UV spectrum of ATZ was calculated using the TD-CAMB3LYP/6-31G* method. The calculated absorption wavelength ($\lambda = 100-400$ nm), excitation energies (E), oscillator strength (f) greater than 0.1, and the participating orbitals in the electronic transitions are reported in Table 5. According to results, the λ_{max} appears at 253.70 nm and the oscillator strength $f = 0.69$ that is due to charge transfer of one electron into the excited singlet state $S_0\rightarrow S_1$ with the participation of three configurations




Fig. 8. Docking hydrogen bonds interactions between the Atazanavir and Coronavirus 2019-nCoV.

including H \rightarrow L (85%), H-2 \rightarrow L (2%), H \rightarrow L+1 (3%). Excitation of an electron from HOMO to LUMO [H \rightarrow L (85%)] is the main contribution for the formation of the absorption band at $\lambda_{max} = 253.70$ nm. As previously mentioned, the electronic transitions from HOMO to LUMO at the λ_{max} are due to the contribution of pi (π) bonds and lone pairs including $\pi\rightarrow\pi^*$ and $n\rightarrow\pi^*$. The calculated UV spectrum of the ATZ molecule is shown in Fig. 6.

The molecular docking analysis is an important tool for drug design and molecular structural biology [29]. The aim of molecular docking analysis is to predict the preferred binding location, affinity, and activity of drug molecules and their protein targets. In the present work, the molecular docking studies of the Atazanavir molecule were performed against Coronavirus 2019-nCoV using HyperChem Professional 08, Molegro Molecular Viewer software programs. The molecular basis of interactions between Coronavirus 2019-nCoV molecule and the Atazanavir can be understood with the help of docking analysis and interactions as observed in Fig. 7. We found 4 positions in which there is a strong




Fig. 7. Interaction of Atazanavir with Coronavirus 2019-nCoV.




Fig. 9. Steric interactions between the Atazanavir and Coronavirus 2019-nCoV.




Fig. 10. Molecular docking of the Atazanavir to Coronavirus 2019-nCoV.

interaction between the drug molecule Atazanavir and the Coronavirus 2019-nCoV that leads to the destruction of the protein structure. The best position is presented here (Fig. 7). The binding energy for Coronavirus 2019-nCoV and Atazanavir is -64.29 kcal/mol in which shows a good binding affinity between the Atazanavir and 2019-nCoV. As seen from Fig. 8 and Table 6 twelve hydrogen bonding formation between reduces Tyr 161, His 163, Thr 135, Gly 138, and His 172 bonded with O atom, Lie 136 and His 172 bonded

with N atoms of the Atazanavir are observed. Steric interactions between the Atazanavir and Coronavirus 2019-nCoV are presented in Fig. 9. It was found that the ligand Atazanavir shows the best affinity towards of the 2019-nCoV compared to other known antiviral drugs: Colistin, Valrubicin, Icatibant, Bepotastine, Epirubicin, Epoprostenol, Vapreotide, Aprepitant in which the binding energy for Coronavirus 2019-nCoV and them is -11.206 , -10.934 , -9.607 , -10.273 , -9.091 , 10.582 , -9.892 and -11.376 kcal/mol that shows the

Table 6
Molecular docking energy data for mentioned ligand and hydrogen bonding.

Protein	Bonded residues	ID	Hydrogen bond	Bond distance (Å)	Binding energy (kcal/mol)
2019-nCoV	Tyr	161	1	1.4390	-5.1104
2019-nCoV	His	163	1	1.2878	-6.5378
2019-nCoV	Thr	135	1	1.4967	-4.2558
2019-nCoV	Thr	135	1	1.5033	-5.4066
2019-nCoV	Gly	138	1	2.5685	-4.7547
2019-nCoV	Lie	136	1	1.9035	-4.9637
2019-nCoV	Ser	139	1	2.8756	-5.1167
2019-nCoV	Ser	139	1	3.1103	-4.7890
2019-nCoV	His	172	1	2.0245	-6.5234
2019-nCoV	His	172	1	2.5439	-5.2279
2019-nCoV	His	172	1	2.0632	-4.1191
2019-nCoV	His	172	1	2.1195	-5.5631

weak binding affinity between them and 2019-nCoV [8]. Molecular docking energy data for mentioned ligand and hydrogen bonding are presented in Table 6 and Fig. 10.

4. Conclusion

In this work, the quantum chemical calculations were carried out for the Atazanavir (ATZ) compound. The geometrical optimized bond lengths and bond angles were calculated theoretically. The HOMO orbital of ATZ is centralized on the N1, N3, O8, and O20, whereas the LUMO orbital is centralized on the N1 atom, double bonds (-C=C- and -C=N-) of one of phenyl and pyrimidine rings. Most of the charge transfer from the HOMO to LUMO in ATZ takes place with the contribution of lone pairs of and pi (π) bonds. The E_C value of ATZ was calculated at about 7.58 eV. In the MEP map of ATZ, the oxygen atoms such as O_a, O_b, O_c, O_d with red color display electron-rich regions which is due to the lone pair electrons, whereas the hydrogen atoms such as H_a, H_b, H_c with blue color show the electron-poor and electrophilic sites. The O20 atom has the highest negative charge (NBO: -0.824e and Mulliken: -0.663e) comparing with other oxygen atoms and the N26 atom has the highest negative charge (NBO: -0.824e and Mulliken: -0.663e) rather than other nitrogen atoms. The theoretical λ_{max} appears at 257.70 nm and the oscillator strength $f = 0.69$ is due to the charge transfer of one electron into the excited singlet state $S_0 \rightarrow S_1$. The binding energy for Coronavirus 2019-nCoV and Atazanavir is -64.29 kcal/mol in which shows a good binding affinity between the Atazanavir and 2019-nCoV. Atazanavir can be used to treat the coronavirus pandemic.

Declaration of Competing Interest

I am Prof.Siyamak Shahab claim that is no conflict between authors of the MS.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.molstruc.2020.129461](https://doi.org/10.1016/j.molstruc.2020.129461).

References

- [1] S.G. Deeks, F.M. Hecht, M. Swanson, T. Elbeik, R. Loftus, P.T. Cohen, R.M. Grant, HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy, *AIDS* 13 (1999) F35–F43.
- [2] D. Fuster, B. Clotet, Review of atazanavir: a novel HIV protease inhibitor, *Expert Opin. Pharmacother.* 6 (2005) 1565–1572.
- [3] B.S. Robinson, K.A. Riccardi, Y.F. Gong, Q. Guo, D.A. Stock, W.S. Blair, B.J. Terry, C.A. Deminie, F. Djang, R.J. Colonna, P.F. Lin, BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents, *Antimicrob. Agents Chemother.* 44 (2000) 2093–2099.
- [4] R.M.M. Cleijns, M.E. van de Ende, F.P. Kroon, F. Verduyn Lunel, P.P. Koopmans, L. Gras, F. de Wolf, D.M. Burger, Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice, *J. Antimicrob. Chemother.* 60 (2007) 897–900.
- [5] R. Wood, Atazanavir: its role in HIV treatment, *Expert. Rev. Anti. Infect. Ther.* 6 (2008) 785–796.
- [6] Ch.J. Achenbach, K.M. Darin, R.L. Murphy, Ch. Katlama, Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults, *Future Virol.* 6 (2011) 157–177.
- [7] G. Li, Y. Fan, Y. Lai, T. Han, Z. Li, P. Zhou, P. Pan, W. Wang, D. Hu, X. Liu, Q. Zhang, J. Wu, Coronavirus infections and immune responses, *J. Med. Virol.* (2020) <https://doi.org/10.1002/jmv.25685>.
- [8] X. Liu, X.J. Wang, Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines, *J. Genet. Genomics.* 47 (2020) 119–121.
- [9] X.Y. Meng, H.X. Zhang, M. Mezei, M. Cui, Molecular Docking: A powerful approach for structure-based drug discovery, *Curr. Comput. Aided. Drug Des.* 7 (2011) 146–157.
- [10] J. de Ruyck, G. Brysbaert, R. Blossey, M.F. Lensink, Molecular docking as a popular tool in drug design, an in silico travel, *Adv. Appl. Bioinforma. Chem.* 9 (2016) 1–11.
- [11] S. Shahab, M. Sheikhi, Triazavirin- Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study, *Curr. Mol. Med.* (2020) <https://doi.org/10.2174/1566524020666200521075848>.
- [12] a) Y. Tawada, T. Tsuneda, S. Yanagisawa, T. Yanai, K. Hirao, A long-range-corrected time-dependent density functional theory, *J. Chem. Phys.* 120 (2004) 8425–8433; b) T. Yanai, D.P. Tew, N.C. Handy, A new hybrid exchange-correlation functional using the Coulomb-attenuating method (CAM-B3LYP), *Phys. Chem. Lett.* 393 (2004) 51–57.
- [13] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery Jr., J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J.M. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, Ö. Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. Fox, Gaussian 09 revision A02, Gaussian, Inc., Wallingford CT, 2009.
- [14] J. Tomasi, B. Mennucci, R. Cammi, Quantum mechanical continuum solvation models, *Chem. Rev.* 105 (2005) 2999–3093.
- [15] E. Runge, E.K.U. Gross, Density-functional theory for time-dependent systems, *Phys. Rev. Lett.* 52 (1984) 997–1000.
- [16] S. Shahab, L. Filippovich, M. Sheikhi, R. Kumar, E. Dikumar, H. Yahyaei, A. Muravsky, Polarization, excited states, trans-cis properties and anisotropy of thermal and electrical conductivity of the 4-(phenyldiazanyl)aniline in PVA matrix, *J. Mol. Struct.* 1141 (2017) 703–709.
- [17] A. Frisch, A.B. Nielson, A.J. Holder, GAUSSVIEW User Manual, Gaussian Inc., Pittsburgh, PA, 2000.
- [18] HyperChem™ Professional Release 8.0 for window molecular modeling system, dealer: copyright © 2002 Hypercube Inc.
- [19] T.A. Halgren, Merck molecular force field. I. Basis, from, scope, parameterization, and performance of MMFF94, *J. Comput. Chem.* 17 (1996) 490–519.
- [20] S. Shahab, M. Sheikhi, L. Filippovich, E. Dikumar, M. Rouhani, A. Pazniak, R. Kumar, Molecular investigations of the new synthesized azomethines as antioxidants: theoretical and experimental studies, *Curr. Mol. Med.* 19 (2019) 419–433.
- [21] R.G. Parr, L.V. Szentpály, S. Liu, Electrophilicity index, *J. Am. Chem. Soc.* 121 (1999) 1922–1924.
- [22] P.K. Chattaraj, D.R. Roy, Update 1 of: electrophilicity index, *Chem. Rev.* 107 (2007) PR46–PR74.
- [23] R.G. Parr, W. Yang, Density Functional Theory of Atoms and Molecules, Oxford University Press, New York, NY, USA, 1989.

- [24] R.G. Pearson, *Chemical Hardness: Applications from Molecules to Solids*, Wiley-VCH, Weinheim, Germany, 1997.
- [25] M. Sheikhi, S. Shahab, L. Filippovich, H. Yahyaei, E. Dikumar, M. Khaleghian, New derivatives of (E,E)-azomethines: Design, quantum chemical modeling, spectroscopic (FT-IR, UV/Vis, polarization) studies, synthesis and their applications: Experimental and theoretical investigations, *J. Mol. Struct.* 1152 (2018) 368–385.
- [26] S. Shahab, M. Sheikhi, M. Khaleghian, Sh Sharifi, S. Kaviani, Theoretical study of interaction between apalutamide anticancer drug and thymine by DFT method, *Chin. J. Struct. Chem.* 38 (2019) 1645–1663.
- [27] S. Shahab, M. Sheikhi, Li. Filippovich, E. Dikumar, H. Yahyaei, R. Kumar, M. Khaleghian, Design of geometry, synthesis, spectroscopic (FT-IR, UV/Vis, excited state, polarization) and anisotropy (thermal conductivity and electrical) properties of new synthesized derivatives of (E,E)-azomethines in colored stretched poly (vinyl alcohol) matrix, *J. Mol. Struct.* 1157 (2018) 536–550.
- [28] F. Weinhold, C.R. Landis, Neutral bond orbitals and extensions of localized, *Chem. Educ. Res. Pract. Eur.* 2 (2001) 91–104.
- [29] N. Ataunal Ancin, S. Gül Oztas, O. Küçükterzi, N. Altuntas Oztas, Theoretical investigation of N-trans-cinnamylidene-m-toluidine by DFT method and molecular docking studies, *J. Mol. Struct.* 1198 (2019) 126868.